River Road Asset Management LLC Makes New Investment in Royalty Pharma plc (NASDAQ:RPRX)

River Road Asset Management LLC bought a new stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 154,639 shares of the biopharmaceutical company's stock, valued at approximately $4,344,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Allworth Financial LP grew its holdings in shares of Royalty Pharma by 89.8% during the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 451 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Royalty Pharma by 112.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 531 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Royalty Pharma by 210.8% during the second quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 546 shares during the last quarter. Rakuten Securities Inc. acquired a new position in shares of Royalty Pharma during the fourth quarter valued at about $110,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Royalty Pharma during the first quarter valued at about $113,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Bank of America cut their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a "buy" rating on the stock in a report on Friday, April 12th. The Goldman Sachs Group lowered their price objective on shares of Royalty Pharma from $56.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, February 20th. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Thursday, April 11th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 20th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Royalty Pharma has a consensus rating of "Buy" and a consensus target price of $46.75.

Royalty Pharma Price Performance

RPRX stock traded up $0.27 during midday trading on Friday, reaching $28.16. The company had a trading volume of 1,775,773 shares, compared to its average volume of 2,648,532. The company has a debt-to-equity ratio of 0.61, a current ratio of 7.90 and a quick ratio of 7.90. Royalty Pharma plc has a 1 year low of $25.92 and a 1 year high of $36.48. The company has a market capitalization of $16.82 billion, a P/E ratio of 14.75, a P/E/G ratio of 0.78 and a beta of 0.45. The firm has a 50-day moving average price of $29.79 and a 200-day moving average price of $28.50.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The business had revenue of $736.00 million during the quarter, compared to analysts' expectations of $702.90 million. On average, research analysts anticipate that Royalty Pharma plc will post 3.95 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 17th will be paid a $0.21 dividend. The ex-dividend date is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.98%. Royalty Pharma's dividend payout ratio (DPR) is 44.44%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.